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Abstract
Micro- and nano- mesoporous silicate particles are considered potential drug delivery systems
because of their ordered pore structures, large surface areas and the ease with which they can be
chemically modified. However, few cytotoxicity or biocompatibility studies have been reported,
especially when silicates are administered in the quantities necessary to deliver low-potency drugs.
The biocompatibility of mesoporous silicates of particle sizes ~ 150 nm, ~ 800 nm and ~ 4 µm and
pore sizes of 3 nm, 7 nm and 16 nm respectively are examined here. In vitro, mesoporous silicates
showed a significant degree of toxicity at high concentrations with mesothelial cells. Following
subcutaneous injection of silicates in rats, the amount of residual material decreased progressively
over three months, with good biocompatibility on histology at all time points. In contrast, intra
peritoneal and intra venous injections in mice resulted in death or euthanasia. No toxicity was seen
with subcutaneous injection of the same particles in mice. Microscopic analysis of the lung tissue of
the mice indicates that death may be due to thrombosis. Although local tissue reaction to mesoporous
silicates was benign, they caused severe systemic toxicity. This toxicity could be mitigated by
modification of the materials.
Introduction
Mesoporous silicates have been studied in the context of drug delivery [1–29], drug targeting
[30,31], tissue engineering [32–35], gene transfection [36–38] and cell tracking [39–42]. The
unique mesoporous structure of these particles is the cause of the broad interest in their
application in biotechnology. Their large internal volumes, high surface areas and straight
narrow channels allow for the high adsorption of drugs and proteins into their structures. The
straight channels allow for adsorbed drugs to diffuse out in a controlled manner over time
frames that depend on the drug in question (size and chemical composition), the release
medium, pore size, surface functionalization and particle size and morphology. Drug release
can occur over minutes, hours or days[2,5–7]. Mesoporous materials also offer the advantage
that the channels can be used as a reservoir and the openings can be opened or closed by
different systems, e.g. polymers[3,9,19,20,30,43,44], nanocrystals [1] or photoactive
derivatives [45]. Triggers such as heat [19,43], pH [3,20,30,44], light[45], chemicals[1],
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ultrasound[9] or magnetism[46] can be used to control drug release. Consequently, there have
been numerous studies of release profiles of drugs from micro- and nano- mesoporous silicates
into simulated body fluid or phosphate buffered saline [1–30].
The biological response to these materials has been much less well characterized. Several
reviews suggest that silica nanoparticles (solgels, xerogels, etc) are biocompatible and degrade
over time in the body [12,25,47,48]. The walls of mesoporous silicates have the same
amorphous silica composition but less is known regarding their inherent biocompatibility and
biodegradability. In vitro cytotoxicity studies exhibit low toxicity at low concentrations [1,
15,17,36,37,39,40] but this toxicity appears to increase at higher concentrations [37]. The
toxicity has been shown to depend somewhat on particle size [24]. In vivo studies with
mesoporous particles 1–2 µm in size have shown little toxicity in small quantities, 1.1 mg and
~4×107 particles (SBA-type (SBA: Santa Barbara Amorphous) and MCM-type (MCM: Mobil
Composition of Matter) respectively) [2,37]. Mesoporous particles (~ 100 nm) fused with iron
oxide amorphous silica particles exhibited low toxicity intravenously in mice [41].
The principal purpose of this research is to evaluate the toxicity of mesoporous silicates
specifically as drug delivery vehicles. In that context, it is important to note that many drug
delivery systems, particularly for local depot applications or for drugs with low potency, may
require considerable amounts of particle to be delivered. For example, poly (lactic-co-glycolic)
acid (PLGA) microparticles loaded with bupivacaine – a relatively potent local anesthetic –
are injected at the sciatic nerve in quantities greater than 200 mg/kg, even though they have a
75% loading with the drug[49]. Similarly, effective coverage of a large body cavity such as
the peritoneum or pleura could require large quantities of particle[50]. In the context of the
peritoneum, we have shown that even massive quantities of PLGA micro and nanoparticles
(100 mg in a 25 g mouse, or 4 g/kg) are well tolerated, although adhesions form in some cases
[50]. Lesser but still substantial quantities (10 mg) of other types of particles are also tolerated
in the peritoneum[51].
Here, we examine the cytotoxicity and biocompatibility of mesoporous silicates that have been
used in biotechnological applications [1–21,23–30,32,33,35–40,43,44,46,47], such as the
MCM-41 and SBA-15. We also examine MCF (MCF: Mesocellular Foam) which is an SBA-
type material with a larger, more disordered pore system [19,52]. The properties of mesoporous
silicates are dependent on the specific synthetic procedures used in their manufacture [53].
Therefore, to ensure comparability and relevance to templating methods used in many
biotechnology applications of mesoporous silicates [1–21,23–30,32,33,35–40,43,44,46,47],
the particles examined in this study are synthesised via the same methods. We have produced
these mesoporous silicates in particle sizes ~ 150 nm, ~ 800 nm and ~ 4 µm and pore sizes of
3 nm, 7 nm and 16 nm respectively, synthesised with cationic and neutral surfactants. We
examine their suitability for drug delivery from a toxicological standpoint, using both in
vitro and in vivo measures.
Materials and Methods
Materials
Tetraethoxysilane (TEOS), cetyltrimethylammonium bromide (CTAB), ethanol, methanol,
hydrochloric acid (37%), sodium hydroxide, sodium chloride, potassium chloride, magnesium
sulphate, calcium chloride, trimethylbenzene (TMB), human insulin, hydrocortisone,
carboxymethylcellulose (medium viscosity) and glutaraldehyde were all obtained from Sigma.
Pluronic P123 (EO20PO70EO20), was obtained from BASF (Badische Anilin- & Soda-Fabrik).
Growth factor, fetal bovine serum, trypsin, DMEM, Medium 199, penicillin/streptomycin and
phosphate buffered saline (PBS) were all obtained from Invitrogen. MTT cell assay kits were
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obtained from Promega. An endotoxin assay kit was obtained from Cambrex Bioscience
Walkersville.
Mesoporous silicate (MPS) syntheses
MCM-41 [36], SBA-15 [54] and MCF [52] were synthesised according to previously published
protocols. The surfactant was removed from MCM-41 by three different methods – refluxing
with acidified methanol (1.5 g of 9 ml of HCl (37 %) in 160 ml of methanol) followed by
washing with methanol, Soxhlet extraction in ethanol for 24 hours or calcination in flowing
air (550°C for 6 hours). The surfactant P123 was removed from SBA-15 and MCF by Soxhlet
extraction in ethanol for 24 hours. All materials were heated under vacuum at 60°C to remove
any residual ethanol/methanol before use for in vitro or in vivo studies.
MPS characterisation
FTIR spectra were obtained with a potassium bromide (KBr) disc of each mesoporous particle.
Elemental analysis was performed to determine the percentage of carbon, hydrogen and
nitrogen on each particle using a CHN analyser (PE-2400II; Perkin-Elmer). Nitrogen gas
adsorption/desorption isotherms were measured at 77 K using a Micromeritics ASAP 2010
system. Samples were pretreated by heating under vacuum at 348 K for 12 h. The surface area
was measured using the Brunauer-Emmett- Teller (BET) method[55]. The pore size data were
analyzed by the thermodynamic-based Barrett-Joyner-Halenda (BJH) method [56] on the
adsorption and desorption branches of the N2 isotherm. Particle size was measured using a
ZetaPALS (Brookhaven Instruments Corportation) and a Multisizer 3 Coulter counter
(Beckman Coulter). Samples were pretreated by sonication and vortexing for 2 hours.
Transmission electron microscopy was conducted using a JEOL JEM 200CX or a JEOL JEM
2010 electron microscope operated at an accelerating voltage of 200 kV. The powder was
suspended in ethanol and placed directly on a carbon-coated copper grid. Scanning electron
microscopy was conducted using a FEI/Philips XL30 FEG ESEM. Samples were dried and
ground before SEM analysis. SEM images were analysed using Gatan Digital Micrograph
Version 3.6.5. Powder X-ray diffraction data was obtained on a Philips X’pert diffractometer
using Ni filtered Cu KR radiation with λ=1.54 Å. Samples were analyzed from 0.3° to 70°
2θ. An endotoxin assay was conducted using the QCL-1000® test kit from Cambrex – samples
were mixed with the LAL reagent and chromogenic substrate reagent over a short incubation
period (16 minutes), and the absorbance was read at 408 nm.
In vitro cell assays
In vitro cell viability in the presence of mesoporous silicates were investigated by MTT and
live/dead cytotoxicity assays using human mesothelial cells line (ATCC, MeT-5a), mouse
peritoneal macrophage cells (ATCC, PMJ2-PC) and mouse myoblast cells, differentiated into
muscle cells (ATCC, C2C12). MPS in media without cells were tested and found not to interfere
with the MTT assay. Human mesothelial cells were cultured in Medium 199, containing Earle’s
salts, L-glutamine and 2.2 g/L sodium bicarbonate and supplemented with 3.3 nM epidermal
growth factor, 400 nM hydrocortisone, 870 nM insulin, 20 mM HEPES, 1% penicillin/
streptomycin and 10% fetal bovine serum. Peritoneal macrophages were cultured in DMEM
medium (GIBCO DMEM 11695-010) containing 1% penicillin/streptomycin and 10% fetal
bovine serum. Myoblasts were cultured and grown in the same media as macrophages but were
differentiated into muscle cells using DMEM with 2% horse serum and 1% penicillin/
streptomycin for 8 days, changing the media every 3–4 days. Cells from passages 5 through
25 were used. Cells were seeded into 24 well plates at a density of 50,000 (mesothelial), 25,000
(macrophage) and 30,000 (myoblast) cells per well. On the eighth day after plating myoblasts
and after overnight incubation of mesothelials and macrophages, 100 µl of MPS suspended in
PBS at different concentrations was added to each well. Control wells received 100 µl of PBS.
Hudson et al. Page 3
Biomaterials. Author manuscript;
The MPS were sterilised by UV irradiation for 2 hours and were suspended in sterile PBS at
concentrations of 1.1, 3.3 and 5.5 mg/ml and sonicated in a Branson 1510 sonicator bath
(Branson Ultrasonics Corp., Danbury, Connecticut) for 2 hours before addition to the cells.
After varying incubation periods, cell viability was assayed either by MTT or live/dead assays.
Results were reported as means and standard deviations of the measured absorbance normalised
to the absorbance of the control cells for the MTT assay.
In vivo studies
All the animals were cared for in compliance with protocols approved by the Animal Care and
Use Committee at the Massachusetts Institiute of Technology, and the Principles of Laboratory
Animal Care (NIH publication #85-23, revised 1985). Young adult male Sprague-Dawley rats
weighing 300–400 g and SV129 mice weighing 25 g were purchased from Charles River Labs
(Wilmington, MA) and housed in groups in a 6 AM-6 PM light dark cycle. Mesoporous silicates
and carboxymethylcellulose were sterilized by UV irradiation for 2 hours.
Carboxymethylcellulose (CMC) was dissolved in sterile phosphate buffered saline (1% w/v).
MPS particles were suspended in 1% CMC and sonicated for 2 hours before being loaded into
1 ml syringes under sterile conditions. Anaesthesia was induced briefly, prior to injection, with
isofluroane in 100% oxygen. Each rat received one subcutaneous injection of 30 mg in 1 ml
of 1% CMC and one intramuscular injection into the sciatic nerve region of 30 mg in 0.6 ml
of 1% CMC. Mice received either one subcutaneous injection or one intraperitoneal injection
of MPS suspended in 1 ml of 1% CMC. Intraperitoneal injections of 1% CMC and the filtrate
from 30 mg/ml 1% CMC after sonication for 2 hours were also given to mice as controls.
Tissues recovered from the necropsy were fixed in 10% formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin for histological examination using standard
techniques. Gram staining of fluid from mice peritoneum was also conducted. Intravenous
injections of the smallest mesoporous silica particles (MCM-41ref) suspended in PBS were
conducted through the mouse tail vein. The volume injected was 0.3 mls of an MCM-41ref
suspension (20 mg/ml) and PBS (0.3 ml) was injected as a control.
Statistics
All comparisons were done with a t-test assuming unequal variance using SPSS 12.0 (SPSS
Inc., Chicago, IL). A p value < 0.05 was considered statistically significant. We corrected for
multiple comparisons by dividing the p value by the number of comparisons (i.e the Bonferroni
correction).
Results
Characterization of mesoporous silicates
Three types of unfunctionalized mesoporous silicates, MCM-41, SBA-15 and MCF, were
synthesized for this study (Table 1). The three types differ greatly in the degree of order of
their pore structure, pore and particle sizes and were synthesised with two different surfactants.
SBA-15 and MCF were prepared with a neutral block co-polymer ethylene oxide-propylene
oxide-ethylene oxide (P123). FTIR studies showed no P123 surfactant present in SBA-15 and
MCF after removal by Soxhlet extraction (repeated refluxing) in ethanol (Figure 1a). MCM-41
was prepared with the cationic surfactant CTAB which is more difficult to remove after
synthesis. Soxhlet extraction in ethanol did not remove CTAB fully. Refluxing in acidified
methanol (MCM-41ref) or heating gradually to 550 degrees Celsius under the flow of air
(calcining, MCM-41cal) removed much more of the cationic surfactant, as indicated by FTIR
(Figure 1b). All 4 MPS (MCM-41ref, MCM-41cal, SBA-15 and MCF) have identical FTIR
spectra and each peak is identifiable with a vibration in mesoporous silica particles, i.e. O-Si-
O bending band ~ 480 cm−1, Si-O bending ~ 800cm−1, SiOH bending ~950 cm−1, Si-O-Si ~
1000–1200 cm−1 and SiOH stretching band ~ 3500 cm−1. Elemental analysis indicated that
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very low amounts of carbon and hydrogen and no nitrogen were present in all 4 samples (Table
1). An endotoxin assay showed that there was no detectable gram negative endotoxin on any
of the four particle types at a concentration of 1 mg/ml, (the detection limit was less than 0.1
EU/ml).
The large surface areas and different pore sizes of the chosen MPS are presented in Table 1.
The ordered mesoporous structure of all three materials is clearly observed from the sharp step
in the nitrogen adsorption/desorption isotherm due to the capillary condensation/evaporation
of the nitrogen gas in the mesopores at different relative pressures, dependent on the pore size
(Figure 2a). MCM-41 had the smallest sized channels and pore openings (~ 3 nm) while MCF,
a mesocellular foam, had much larger pores. MCF was more disordered, consisting more of
cell-like structures (40 nm wide) with narrow openings (16 nm) as calculated from the
adsorption and desorption branches of the isotherm respectively. SBA-15 and MCM-41 both
had hexagonally highly ordered straight channel pores, as illustrated by the low angle XRD
spectra in Figure 2b and in the TEM images in Figure 3. The unit cell parameters (a) of the
three hexagonally ordered materials are listed in Table 1. The particle sizes of the three
materials are given in Table 2 and can be seen in the SEM images in Figure 3. MCM-41 and
SBA-15 consisted of regularly ordered spheres (100 – 150 nm) and rods (700 – 800 nm)
respectively, while MCF particles were much larger (~ 4 µm) with a more irregular
morphology. MCM-41 had similar physical characteristics whether refluxed or calcined, i.e.
particle size, morphology and pore size, although MCM-41ref had a lower surface area than
MCM-41cal, as calculated by the BET theory [55].
Some aggregation was observed as evidenced by the difference in the particle sizes measured
by SEM compared to those measured in phosphate buffered saline after sonication and
vortexing (the usual preparation of the materials for cytotoxicity and in vivo experiments) using
ZetaPALS and Coulter counter size analysers (Table 2). Particle sizing, TEM and SEM
analyses showed that the particle sizes were not changed by UV sterilization, sonication for 2
hours and incubation for 4 days in PBS at 37°C (not shown), showing that particles would be
stable in the conditions used in vitro.
Cytotoxicity of materials
Human mesothelial cells, mouse peritoneal macrophages and mouse myoblasts differentiated
into muscle cells were exposed to varying amounts of mesoporous silicates (Figure 4–Figure
6). MCM-41soxhleted was very toxic to all cell lines examined (not shown) at all concentrations
and time points, (0.1, 0.3 and 0.5 mg/ml and 24, 72 and 96 hours). Consequently,
MCM-41soxhleted was not used in subsequent studies. In general the toxicity of MCM-41cal,
SBA-15 and MCF to mesothelial cells and myoblasts increased with the concentration of
particles, most significantly with the mesothelial cell line. Macrophages showed little or no
toxicity from those three particle types, Figure 4. MCM-41ref was more toxic to the
macrophages (p < 0.0001 for 0.5 mg/ml at 4 days, compared to all other MPS) (Figure 4) and
exhibited a lower toxicity to the mesothelial cell line (p < 0.0001 for 0.5 mg/ml at 4 days,
compared to all other MPS, Figure 5). In order to verify that cytotoxicity was not due to particles
landing on top of the cells and inhibiting nutrient or oxygen uptake, the mesothelial cell viability
experiments were repeated with the particles added before the cells had been plated; the results
were identical. To assess whether toxicity was due to the particles themselves, or a soluble
factor that was released, 5.5 mg of SBA-15 per ml of mesothelial medium were sonicated and
vortexed for 2 hours and incubated at 37°C for 4 days. TEM and SEM imaging indicated that
the particle size and mesoporous structure were unchanged. The pH of the medium was also
found to be unchanged after this treatment. Subsequently, mesolthelial cells were incubated
for four days with either the SBA-15 supernatant or the particles. The SBA-15 supernatant did
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not affect cell viability while the SBA-15 particle suspension (0.5 mg/ml) killed 50% of cells
present.
In vivo studies
In vivo experiments were carried out using 1% carboxymethylcellulose as a carrier, unless
otherwise stated, due to the tendency of the larger MPS to fall out of suspension. Particles were
injected subcutaneously and at the sciatic nerve in rats; the latter location was selected because
of the close proximity of many different tissue types (nerve, muscle, blood vessels, connective
tissue). MCM-41cal, MCM-41ref, SBA-15 and MCF were injected at a concentration of 50 mg/
ml at the sciatic nerve. The same animal was injected with 1 ml of the same suspension at a
concentration of 30 mg/ml subcutaneously on the contralateral limb. At predetermined time
points (Table 3), rats were sacrificed for necropsy. One rat injected with MCM-41cal particles
developed difficulty moving its hind limbs on the second day after injection and was
euthanized, and one injected with MCM-41ref particles died 3 days after injection. All other
rats (n = 40) injected with mesoporous silicates did not exhibit any overt toxicity, including
gait abnormalities on the side where the sciatic nerve injections were performed.
Grossly, MPS materials disappeared from the sciatic nerve region much faster than from the
subcutaneous depot, i.e. in general much smaller amounts of all four MPS were recovered. At
early time points, quite large deposits of material were found subcutaneously (Figure 7a–c).
Irrespective of the site of injection, very small amounts or no MPS materials were observed at
the two and three month points (Figure 7d–f). In many cases, MPS were detected on histological
assessment of tissues at two and three months, even though no or very small amounts of MPS
were observed on gross dissection, Figure 8.
Similar histologic observations were made with all four particle types. There was an
inflammatory reaction to the particles which decreased substantially from the 4 day to the 3
month time points. There was no significant injury to surrounding tissues (muscle, nerve, blood
vessels). At the 4 day time point, the inflammation consisted predominantly of neutrophils with
some macrophages. The inflammation decreased over time and became dominated by
mononuclear cells such as lymphocytes and macrophages. The surrounding tissue showed
evidence of healing, with granulation tissue formation and mild fibrosis over time. The spleens
of all the rats injected were without focal lesions on gross dissection. Histologically, there was
expansion of the red pulp, predominantly by foamy macrophages, noticeable at the earlier time
point of 4 days for the nanoparticles (MCM-41) and at two weeks for the larger microparticles
(MCF). The spleens exhibited progressively less red pulp expansion over the 3 month time
course of the experiments.
To assess the applicability of MPS for intraperitoneal use, particles were injected into SV129
mice (Table 4), a model we selected because of our extensive experience with it for testing
intraperitoneal drug delivery [50]. All mice appeared healthy at 5 hours after IP injection of
all doses assessed here. Mice that received intraperitoneal injections of 30 mg of mesoporous
silicates of all sizes either died or became sufficiently distressed within 24 hours that they were
euthanized. To find the upper limit of the non-lethal dosage range, we injected animals with
decreasing doses of SBA-15 (Figure 9), which had been uniformly fatal at 30 mg. Mice injected
with 10 mg or 5 mg of SBA-15 that needed to be euthanized became ill 30–40 hours after
injection. Doses of 1 mg or less were non-fatal. On necropsy, the viscera of the spontaneously
deceased and euthanized animals had a glistening quality, but there was no obvious injury,
hemorrhage or other catastrophic pathology. Histologic evaluation of the peritoneal cavity
revealed reactive mesothelial cells with only mild acute and chronic inflammation and no
evidence of necrosis of the underlying abdominal wall musculature (Figure 10).
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To elucidate the cause of death of the animals injected with intraperitoneal MPS, samples of
peritoneal fluid from the surface of the viscera of the deceased or euthanized animals were
examined microscopically. Gram staining did not reveal bacteria, and hematoxylin-eosin
staining showed only occasional white blood cells, suggesting the absence of a massive
inflammatory process (i.e. peritonitis) and correlating with the histologic evaluation. To
address the possibility that toxicity was due to the release of a toxic soluble factor, 2 groups
of MPS (MCM-41ref and SBA-15) were sonicated and vortexed for 2 hours and the
supernatants (filtered through a 0.2 µm sterile filter) was injected intraperitoneally. There were
no detectable sequelae. Similarly, injection of the carrier for all intraperitoneal injections, 1%
CMC, did not cause toxicity (Table 4).
Our hypothesis regarding the difference in toxicity between the rat and murine data was that
this was due to a combination of a large difference in dose/weight (0.17 g/kg and 1.2 g/kg
respectively), and pharmacokinetics (intraperitoneal delivery of a toxic material is likely to
result in more rapid systemic distribution, and therefore toxicity, than subcutaneous injection).
The greater toxicity of MPS to mesothelial cells than to other cells (Figure 5) raised the
possibility that peritoneal injury was the cause of death. However, intravenous injection of
MPS (Table 4) uniformly resulted in rapid death, suggesting that the toxicity was not peritoneal
in origin (as did the benign peritoneal histology). The view that pharmacokinetics played a
significant role was bolstered by the fact that mice injected with 30 mg of MPS (Table 4)
subcutaneously did not experience detectable toxicity. The MPS appeared to have the same
generally benign local biocompatibility seen with subcutaneous injections in rats: two months
after injection in mice, small quantities of SBA-15 and only trace MCM-41 were found. Light
microscopy of the lungs from animals that received MPS intravenously or at high doses
intraperitoneally revealed blood clots reflecting either in situ thrombi or emboli in the
pulmonary arteries, arterioles and capillaries. The lungs of the animals injected with the carrier
(1% CMC) or low doses of MPS subcutaneously did not have these clots and appeared normal
(Figure 11).
Discussion
All three materials, MCM-41, SBA-15 and MCF have been suggested in the literature for use
as drug delivery systems, and as formulated here have the mesoporous structure advocated in
the literature to release adsorbed drugs in a controlled manner [1,3,19]. While tissue
biocompatibility for all particles was adequate, or at least comparable to that seen with many
other particle types when delivered in large quantities [50], the systemic toxicity was much
worse than that of more commonly used polymeric delivery systems. Thirty mg of
intraperitoneally injected silicates invariably resulted in death or distress necessitating
euthanasia; in contrast, even 100 mg of poly(lactic-co-glycolic) acid (PLGA) microspheres
caused no detectable toxicity in mice of the same strain and mass [50]. Since an absence of
lethality was only found at a dose of 1 mg per animal, the silicates tested here would appear
to be at least 100 times more lethal than PLGA. We also note the experimental design used
here could not detect more subtle forms of toxicity. These findings do not mean that
mesoporous silicates cannot or should not be used for drug delivery. However, given the above
it would appear prudent to use other systems unless the mesoporous silicates can be shown to
be vastly superior in terms of their release or targeting properties. This would be particularly
true if large quantities of particle are to be used. It is also possible that the toxicity of the
mesoporous silicates could be mitigated by surface adsorption of proteins, functional groups
or polymers [20,51]. Blumen et al [37] indicated that pegylated mesoporous silicates were non-
toxic in peripheral lung tissue. Such pegylation or other coating strategies may also reduce
toxicity systemically.
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All three particle types showed varying degrees of cytotoxicity in vitro. Soxhleted MCM-41
was extremely cytotoxic to all three cell lines, presumably due to the residual cationic surfactant
present in its pores. The toxicity of the MPS was due to interaction with the particles
themselves, rather than with a product of particle degradation, as shown by the 100% cell
survival in the experiments where cells were exposed to particle-free supernatants from a
suspension of SBA-15. Toxicity to mesothelial cells and C2C12 cells was also not likely to be
due to impairment of diffusion of oxygen and nutrients since it made no difference to cell
survival whether the particles were added before or after (i.e. on top of) the cells were plated.
Cell death increased with duration of exposure. In general, MCM-41ref was less toxic to
mesothelial cells but slightly more toxic to macrophages than the other particles. Overall, the
MPS toxicity to mesothelial and C2C12 cell lines (and macrophages with MCM-41ref)
appeared to be dose dependent and exhibited time dependence with the mesothelial cell line.
Particle size (or mesoporous structure) had no bearing on the in vitro cytotoxicity of
mesoporous silicates, within the range of particle sizes examined here (150 – 4000 nm).
In all particle groups, there were still MPS particles present both in the sciatic nerve region
and subcutaneously at up to 3 months, and the rate of decrease in size of the subcutaneous
nodules was grossly similar for all 4 particle types and sizes. The amount of residue remaining
was particularly difficult to assess in the sciatic nerve region, but histology revealed its presence
for up to 3 months. The inflammatory response in vivo was comparable to PLGA [50], a
biomaterial commonly used in drug delivery. Particle size (in the range studied, 150 nm – 4
µm) did not appear to affect biocompatibility although the two rats that became ill both were
injected with the smaller (150 nm) MCM-41 particles. The destination of the particles as the
subcutaneous nodule decreases in size was not determined but subtle changes in the architecture
of the spleens of the rats were observed at earlier time points for the smaller particles (4 days)
and later time points (2 weeks) for the larger particles. This suggests that the smaller particles
(MCM-41) reached the spleen faster than the larger particles, in particular MCF. After 2 or 3
months the spleens had regained their normal architecture.
Mice injected with all 4 types of MPS particles intraperitoneally died or were euthanized within
24 hours of injection at doses of 30 mg. The non-fatal dose was below 5 mg. MCM-41 particles
were toxic intraperitoneally, whether the porous particles were extracted by calcination
(heating to 550°C) or refluxing in acidified methanol, indicating that the toxicity is due to the
particles themselves. This is confirmed by the fact that supernatants in which the particles were
incubated were not detectably toxic. Our efforts to establish the cause of the toxicity suggested
that endotoxin (negative assay), bacterial infection (negative Gram stain), and/or peritonitis
(absence of inflammatory cells) were unlikely causes, and intravenous toxicity demonstrated
that this toxicity did not originate in the peritoneum. The higher death rate in animals injected
in the peritoneum compared to subcutaneously may be due to the faster rate of clearance of the
silica particles from the former site, resulting in a higher systemic dose of the mesoporous
particles. It is possible, given the rapidity of death and the findings on necropsy, that pulmonary
embolism and/or thrombosis were the cause of death. While the etiology of the pulmonary
clots is not clear, it bears mentioning that colloidal silica is pro-thrombotic [57] and that
amorphous silica can cause complement activations [58]. The role of these mechanisms, if any,
in the pathogenesis of our observations is unclear.
Conclusions
Unfunctionalised mesoporous silicates of particles sizes 150 nm – 4000 nm exhibit benign
local biocompatibility but considerable systemic toxicity. This toxicity appears to result from
the particles themselves and not from any contaminants or degradation products. These
findings suggest that biomedical applications of mesoporous silicates should be explored in
the context of modifications to reduce toxicity.
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Figure 1.
FTIR spectra of (a) P123, SBA-15 and MCF and (b) CTAB and MCM-41 soxhleted, refluxed
and calcined. Asterisk (*) indicates the modes of vibration of the P123 surfactant, removed
from both SBA-15 and MCF. Dagger (†) indicates the modes of vibration of the CTAB
surfactant, still present in MCM-41 soxhleted but removed from MCM-41ref and
MCM-41cal.
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Figure 2.
(a) Nitrogen adsorption isotherms and (b) low angle XRD spectra for MCM-41cal, SBA-15
and MCF. Arrows indicate the width of the pore openings as calculated from the desorption
branch of the nitrogen isotherm using BJH theory (see Methods).
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Figure 3.
SEM (left) and TEM (right) images of MCM-41ref, MCM-41cal, SBA-15 and MCF.
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Figure 4.
% Cell survival of macrophages upon exposure to MPS for (○) 1 day, (□) 3 days and (◊) 4
days. n = 16 to 24 for individual groups, assessed using an MTT cell viability kit.
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Figure 5.
% Cell survival of mesothelial cells upon exposure to MPS for (○) 1 day, (□) 3 days and (◊) 4
days. n = 16 to 24 for individual groups, assessed using an MTT cell viability kit.
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Figure 6.
% Cell survival of C2C12 muscle cells upon exposure to MPS for (○) 1 day, (□) 3 days and
(◊) 4 days. n = 16 to 24 for individual groups, assessed using an MTT cell viability kit.
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Figure 7.
MCF subcutaneous nodule (a) 4 days, (b) 2 weeks and (c) 1 month after injection (30 mg) and
(d) MCF, (e) SBA-15 and (f) MCM-41cal 3 months after injection near the sciatic nerve (30
mg). Instruments in the fields indicate residue.
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Figure 8.
Light microscopy of subcutaneous nodules of SBA-15 at (a) 4 days and (b) 3 months and sciatic
nerve injection site of SBA-15 at (c) 4 days and (d) 3 months. Arrows indicate MPS material,
SN – sciatic nerve, M – muscle, I – inflammation. All images are 40x the original magnification.
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Figure 9.
Percentage survival of mice injected intraperitoneally with 1 ml of SBA-15 suspension.
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Figure 10.
(a) Mouse peritoneum 24 hours after IP injection with MCM-41ref (30 mg). Arrows indicate
small pockets of residue. (b) Light microscopic tissue analysis of mouse peritoneum after
SBA-15 (30 mg) IP injections. Arrows indicate mesothelial cells, M – abdominal muscle.
Image (b) is 100x the original magnification.
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Figure 11.
Light microscopy of lung tissue from mice after injection of (a) 1% CMC control
intraperitoneally, (b) MCM-41ref (6 mg) intravenously, (c) and (d) MCM-41ref (30 mg)
intraperitoneally, low and high magnification respectively. Arrows indicate blood clots. Images
(a–c) are 100x and (b) is 400x the original magnification.
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Table 2
Particle sizes of mesoporous silicates as measured using SEM, Zetasizer and Coulter Counter equipment.
Method of Measurement
Material SEM (nm) Zetasizer (nm) Coulter counter (nm)
MCM-41ref 100–150 470±252 -
MCM-41cal 100–150 270±38 -
SBA-15 600–800 740±160 -
MCF 4000–5000 4700±1150 5270±4000
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Table 4
Mortality rate of mice after injection of mesoporous silicates.
Route of Injection Material Dose (mg) Mortality Time to death
Intraperitoneal* MCM-41cal 30 8 of 8 24 hrs
MCM-41ref 30 4 of 4 24 hrs
SBA-15 30 9 of 9 24 hrs
MCF 30 8 of 8 24 hrs
1%CMC 0 of 7 -
Supernatant from MCM-41ref 0 of 2 -
Supernatant from SBA-15 0 of 3 -
Subcutaneous* MCM-41ref 30 0 of 4 -
MCM-41cal 30 0 of 2 -
SBA-15 30 0 of 2 -
Intravenous** MCM-41ref 6 2 or 2 <15 mins
*
Injected in 1% CMC.
**
Injected in phosphate buffered saline.
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